Registration is now OPEN for the CMAC Virtual Open Day taking place across two afternoons of Wednesday 21st and Thursday 22nd October 2020.
On Day 1 of the conference, we will hear from across the Medicines Manufacturing Community including UKRI representatives on their views on how critical mass investments such as CMAC play a role in this dynamic landscape in addition to the Medicines Manufacturing Industry Partnership perspective on the talent and skills requirements to meet future manufacturing needs.
Day 2 will provide opportunity to see and hear exciting recent Hub research outputs including developments in MicroFactory and Digital Twins. There will also be opportunities for e-poster, networking and interactive breakout sessions, along with a panel discussion on the post-COVID landscape.
You can register to attend here.
Massimo Bresciani, Industry Director at CMAC Future Manufacturing Hub will also be presenting at the next TSK Live Conference, for more information please click here.
CMAC’s vision is to revolutionise the way pharmaceuticals and high value products are made. The approaches developed and adopted within CMAC have been developed through close collaboration with industry and the support of its Tier 1 partners, which includes GlaxoSmithKline, AstraZeneca, Bayer, Lilly, Novartis, Pfizer, Roche and Takeda. Established in 2011, the CMAC has a £150m funding portfolio and currently comprises more than 130 staff and researchers, including academics, post docs, and more than 45 PhD students, as well as an experienced support team.